Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for <i>Helicobacter pylori</i> eradication: a phase III, randomised, double-blind study

Kazunari Murakami, Yuuichi Sakurai, Madoka Shiino, +3

Gut

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

Yuuichi Sakurai, Akira Nishimura, Gale Kennedy, +8

Clinical and Translational Gastroenterology

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole

Kiyoshi Ashida, Katsuhiko Iwakiri, Naoki Hiramatsu, +5

World Journal of Gastroenterology

Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

Yoshikazu Kinoshita, Yuuichi Sakurai, Madoka Shiino, +6

Current Therapeutic Research

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis

Katsuhiko Iwakiri, Yuuichi Sakurai, Madoka Shiino, +6

Therapeutic Advances in Gastroenterology

Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study

Yoshikazu Kinoshita, Yuuichi Sakurai, Nobuyoshi Takabayashi, +5

Clinical and Translational Gastroenterology

Cardiovascular DiseaseGastrointestinal PharmacologyMedicineHeartburn ResolutionGastroenterology +8

Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study

Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto, +3

Advances in Therapy

Drug SafetyAntibioticsTriple TherapyPharmacologyPharmacotherapy +5

Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men

Yuuichi Sakurai, Madoka Shiino, Sayako Horii, +4

Clinical Drug Investigation

Tu1056 A Phase 3, Double-Blind Study of a Triple Therapy With TAK-438, Amoxicillin, and Clarithromycin As First Line Eradication of H. pylori and a Triple Therapy With TAK-438, Amoxicillin, and Metronidazole As Second Line Eradication of H. pylori

Kazunari Murakami, Yuuichi Sakurai, Madoka Shiino, +3

Gastroenterology

Health SciencesAntibioticsTriple TherapyAntibiotic AdjuvantPharmacology +8

Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial

Jiaming Qian, Shutian Zhang, Ning Dai, +8

Chinese Medical Journal